Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. (2017)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2468-1253(17)30246-7
PubMed Identifier: 28818518
Publication URI: http://europepmc.org/abstract/MED/28818518
Type: Journal Article/Review
Volume: 2
Parent Publication: The lancet. Gastroenterology & hepatology
Issue: 10